Newly Listed Stocks Born in the Battlefield, Some Plummet to 1/10th of Offering Price

In the current challenging stock market, newly listed stocks are experiencing significant declines from their offering or reference prices. Some stocks have fallen to one-tenth of their offering price, and many have dropped by half. likening this market situation to a 'battlefield,' we have selected newly listed stocks born amidst it as 'Jupjup Series' stocks, covering Inventera, Remedy, Madup, StradVision, KP Aero Industries, SemiTS, Xvis, and Deokyang Energy. Some of these stocks were listed through public offerings, while others went through SPAC listings.

Inventera possesses technology to solve the 'protein corona phenomenon,' a major challenge in nanomedicine. The protein corona phenomenon occurs when nanoparticles entering the body bind with various proteins in the blood, forming a protein layer on their surface. This phenomenon has been identified as a primary cause of reduced drug efficacy and increased side effects due to the engulfment by immune cells. The company explains that the type and structure of the protein corona bound to the surface, rather than the intrinsic properties of the nanoparticle itself, are key factors in determining whether immune cells will engulf them.

Inventera's 'Infinity Platform' is a versatile nanomedicine platform that can be expanded for various uses, from contrast agents to therapeutics, depending on the payload. This adaptability is a key differentiator for Inventera's technology. The platform has resolved the issue of stability breakdown caused by changes in the overall charge of particles when loading drugs or metals. Through its charge control technology, Inventera can freely adjust the surface charge of nanoparticles to be positive or negative, matching the characteristics of the loaded substance. This significantly enhances the stability and utility of nanomedicines. Such flexibility is expected to open up possibilities for various new drug developments.

Remedy possesses unique technological capabilities in developing compact, portable X-ray devices. Only about three companies worldwide have such technology, and Remedy is reportedly the only one in Korea. MinXray in the US and Fujifilm in Japan are the other companies possessing this technology. Remedy's biggest technological moat lies in its ability to miniaturize two core components to create X-ray devices. This offers the advantage of maximizing portability in medical settings, thereby increasing their utility.

A major drawback for Remedy has been the heavy reliance on revenue from India, raising concerns that this might be perceived as event-driven business. However, the company explains that X-ray devices need to be replaced every three years, and about 20% of total revenue comes from component sales. Especially in fields like tuberculosis diagnosis, the business has characteristics that necessitate its continuation, asserting stability from a long-term perspective. While high dependence on the Indian market remains a potential risk factor, continuous replacement cycles and component sales can provide a stable revenue base.

The automotive industry has recently shown a tendency to focus on Level 2 (L2) and Level 2 Plus (L2+) autonomous driving technologies rather than fully autonomous Level 4 (L4) and Level 5 (L5). While Tesla's vision for full autonomous driving in 2019 raised expectations for a rapid arrival of the L4 and L5 era, the actual market has moved differently.

This is due to several factors, including technological limitations, unpredictable emergencies, and vast data processing challenges. The most crucial issue, however, is the legal and ethical question of who bears responsibility in case of an accident. Due to these complex reasons, manufacturers are prioritizing the development and dissemination of L2 and L2+ technologies, which are closer to commercialization.

Autonomous driving technology company StradVision faces investment uncertainty due to the difficulty in confirming specific business information such as royalty revenue and per-unit prices. Despite the company touting 5 million units of mass production experience at the time of listing, it was difficult to ascertain information regarding actual revenue and per-unit profits. Inquiries made via phone or email to the company went unanswered, raising questions about information transparency.

Even recent figures do not clearly indicate how much profit will be generated when they lead to Mass Production (MP). While StradVision's technology itself is highly regarded, the lack of information related to actual profit generation capabilities makes investment decisions challenging.

Madup is moving away from labor-intensive operational methods in advertising and marketing by utilizing its self-developed AI solution, 'Lever Expert.' This solution allows AI to handle over 80% of repetitive tasks performed by marketers. Specifically, it automates significant portions of advertising data collection, performance analysis, effective ad selection, budget adjustments, and results reporting.

This provides high-efficiency agency services based on technology, maximizing human resource efficiency and allowing marketers to focus on more strategic and creative tasks. Madup's approach is considered a key strategy to enhance efficiency and productivity in response to changes in the digital advertising market. This innovation through AI technology has the potential to reshape the advertising market.

Madup's stock price has risen by over 100%, exceeding market expectations. This demonstrates that the market's demand for AI-driven advertising is much greater than anticipated. In contrast, despite StradVision's technological advantages and potential, an analysis suggests that market attention is currently focused on other sectors rather than autonomous driving, leading to disparities between stocks. Madup's success shows that AI technology is acting as a strong growth engine in the advertising market.

KP Aero Industries operates with aerospace, defense, and space industries as its three major business pillars. In the aerospace sector, it supplies core components such as wings and airframe structures to global aircraft manufacturers like Boeing, Airbus, and KAI, both domestically and internationally. Notably, it holds 60-70% of the global market share for wingtip structures.

In the defense sector, it provided technology for the Cheongung 2 project, a key interceptor for K-defense. The most remarkable aspect is its space business, where in June 2025, it successfully conducted the world's first large titanium high-pressure vessel extreme test for a 3D-printed space launch vehicle. This marks the world's first instance of a large titanium alloy high-pressure tank produced by 3D printing passing extreme condition tests simulating actual space environments. This innovative technological capability is considered a core competitiveness of KP Aero Industries.

SemiTS provides essential logistics infrastructure based on AMHS (Automated Material Handling System) for stable and efficient wafer transport in semiconductor production lines. Its main products are clean conveyor systems and nitrogen purge systems. Due to the nature of the semiconductor equipment industry, securing references is crucial because once technology is verified and applied in a fab, recurring orders and expansion to other fabs are likely. These proven references create a potential lock-in structure that acts as a strong barrier to entry.

SemiTS maintains a debt-free management policy and boasts a solid financial structure with an average operating profit margin of 28%. This demonstrates consistent profitability based on a stable business model and high technological competitiveness.

While Kenkooa Aerospace and KP Aero Industries both operate in aviation-related businesses, they differ in their primary revenue sources. Kenkooa Aerospace focuses on aircraft maintenance, repair, and overhaul (MRO), whereas KP Aero Industries is analyzed to have a higher proportion of defense revenue. These differences impact the business models and growth strategies of the two companies.

Readers expressed curiosity about the distinctions between the two companies and requested a detailed comparison of their MRO and defense revenue proportions. This information will be crucial for investors to understand each company's core competitiveness and make investment decisions.

An analysis suggests that the core valuation of KP Aero Industries in the market lies in its 3D printing titanium processing technology rather than aviation maintenance assembly or MRO (Maintenance, Repair, and Overhaul). The company's 3D printing capabilities, especially its ability to process highly challenging materials like titanium, are considered a unique competitive advantage for KP Aero Industries.

This technology is well-demonstrated by the world's first instance of 3D printing a large titanium high-pressure vessel for space launch vehicles and passing extreme environment tests. Therefore, investors need to focus on this 3D printing titanium processing technology when evaluating KP Aero Industries' value. This will be an important indicator for gauging the company's future growth momentum and potential.

Deokyang Energy is a company specializing in high-purity refining of industrial byproduct hydrogen. Its business model differs from hydrogen companies known for hydrogen refueling. Deokyang Energy operates as an industrial hydrogen infrastructure company that refines byproduct hydrogen generated at industrial sites to produce and supply high-purity hydrogen. This business model contributes to building essential hydrogen supply chains for specific industrial sectors.

Hydrogen is classified into various types, such as gray hydrogen, blue hydrogen, green hydrogen, and pink hydrogen, depending on its production method and carbon emissions. Generally, hydrogen produced from petroleum processes is classified as 'gray hydrogen' and has high carbon emissions. If the carbon generated during this gray hydrogen production process is captured and stored, it becomes 'blue hydrogen.'

'Green hydrogen' is obtained by electrolyzing water using renewable energy, and it is considered the most environmentally friendly hydrogen as it has no carbon emissions. 'Pink hydrogen' refers to hydrogen produced using nuclear energy. This color-based classification serves as an important benchmark for assessing the environmental friendliness of the hydrogen industry.

A criticism has been raised that Deokyang Energy's business direction diverges from the government's policy of promoting green hydrogen and phasing out gray hydrogen. While the government emphasizes the transition to an eco-friendly hydrogen economy and focuses on green hydrogen, Deokyang Energy's primary business is refining byproduct hydrogen, leading to questions about its inconsistency with policy direction.

In this situation, interest in Deokyang Energy's competitiveness and investment points is growing. Industrial byproduct hydrogen remains an important industrial raw material, and establishing a stable supply chain based on existing infrastructure and technological capabilities could be Deokyang Energy's core competitiveness. How a company with a business model different from government policy will maintain competitiveness and grow in the market is a key observation point for investors.

Remedy has secured a dominant position in the portable medical equipment market based on its compact, portable X-ray technology, weighing 1-2 kg. Other X-ray product manufacturers in Korea, such as Vatech, Genoray, and DRTECH, can produce large mobile or dental equipment, but not portable medical equipment. This technological difference has been the main factor allowing Remedy to preempt this market.

Portable X-ray equipment has significant market potential as it can be used in various environments, such as medically underserved areas or emergency situations. Remedy's unique technological capabilities are also expected to play a crucial role in achieving the company's goal of providing high-quality medical imaging at low cost.

Remedy has shown improved performance but is struggling to rebound its stock price. Chart analysis indicates that while the company's performance has shown positive changes, its stock price has not seen a corresponding rebound. This suggests that the market may not be fully reflecting Remedy's improved performance, or other external factors might be at play. Further analysis of future stock price trends seems necessary.

Skylabs, currently preparing for an initial public offering (IPO), is a company developing a ring-type form factor. This company is eligible for domestic insurance coverage and has applied for US FDA approval, aiming to secure reimbursement through expansion into the US and international markets. Notably, Skylabs has established a stable sales network through a sales collaboration with the domestic pharmaceutical company Daewoong. This strategy is expected to be a significant aid in market entry and expansion.

The collaboration with Daewoong will provide a crucial foothold for Skylabs' developed medical devices to effectively reach a wider market. Funds raised through the IPO are expected to be utilized for research and development and expansion into overseas markets.

Xvis has achieved the top position in domestic supply in the mobility sector. This demonstrates that Xvis's technology and products have high competitiveness in the domestic mobility market. It is solidifying its position as a market leader by supplying core components and solutions to major domestic mobility companies. These achievements mean that Xvis's technology is widely adopted in the actual market.

SemiTS secures a competitive advantage over rivals by providing integrated solutions necessary for semiconductor logistics automation, including clean conveyor systems, smart OHT (Overhead Hoist Transport), nitrogen purge control systems, and maintenance services. Unlike its competitors, SFA which focuses on logistics systems, and Justem which specializes in purge systems, SemiTS offers customized solutions to clients by integrating various products and services.

This ability to provide integrated solutions maximizes the efficiency and stability of semiconductor production lines, offering one-stop services to clients and leading to high satisfaction. SemiTS's strategy is evaluated as a strong competitive advantage in the market and is expected to contribute to building a long-term growth foundation.

Remedy has a relatively small total number of issued shares, approximately 7 million, and with the founder and 40 others holding about 40% of the shares, it is classified as a 'scarce stock' with low liquidity. This stock structure can contribute to increased stock price volatility in the market. At the same time, Remedy emphasizes corporate social responsibility, aiming to provide high-quality medical imaging at low cost to medically underserved populations.

This demonstrates the company's commitment to contributing to social good beyond mere commercial profit-seeking with its technology. Along with the low number of floating shares, these social goals can serve as factors that appeal to investors regarding the company's long-term vision and value.

An analysis indicates that despite Xvis allocating nearly 80% of its capital to facility investments (CAPEX), its stock price remains undervalued, failing to fully reflect the value of these investments. Even though large-scale facility investments lay crucial groundwork for future growth, the stock price has not rebounded in the market and has given back all gains. This undervaluation suggests that Xvis is not currently receiving adequate recognition in the market.

Therefore, it has been suggested that Xvis likely holds high investment value at its current stock price level, and if the company's growth potential and the effects of facility investments are reflected in the stock price in the future, it could have significant upward potential. Investors need to approach Xvis from a long-term perspective.

In the stock Olympics voting, the opinion was raised that votes should be cast for stocks with great potential for future growth rather than those that are currently good. It was emphasized that it is important to objectively judge which stock has the highest growth potential at the current moment, rather than simply voting for stocks one already owns. For example, even if one owns Rainbow Robotics, it cannot be definitively said that it will rise more than Robotis. Therefore, the voting should be based on which stock one would invest in if they had fresh money.

This implies the need for an objective perspective to evaluate future value and to make rational investment decisions without being swayed by emotional factors or current holdings. This approach will uphold the original spirit of the stock Olympics and contribute to identifying truly promising stocks.